Molbio Diagnostics Limited

Sector: Molecular Diagnostics / Point-of-Care (POC) Medical Devices & Consumables

1. Executive Overview

Molbio Diagnostics Limited is an innovative point-of-care ("POC") molecular diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies for diagnosing infectious and non-communicable diseases. The Company's core innovation is its 'Truenat' platform — a novel, battery-operated POC polymerase chain reaction ("PCR") platform capable of operating in resource-limited settings and delivering decentralised diagnosis within an hour. As of March 31, 2026, Truenat was patented in more than 100 countries and offered molecular testing for 30 diseases — including tuberculosis ("TB"), COVID, Hepatitis B and C, HIV and HPV — across 43 assays.

The Company operates a razor-and-blade model: it sells the Truenat instrument platform (razor) which works exclusively with proprietary, single-use Truenat test kits (blades) that generate high-margin recurring revenue. The business is anchored by strong in-house R&D executed through its wholly-owned subsidiary Bigtec Private Limited (Bengaluru), whose platform underwent 13 years of R&D to obtain ICMR certification. Molbio's Truenat TB test chip is the only one developed by an Indian company and one of only two rapid molecular tests globally endorsed by the World Health Organization ("WHO") for initial diagnosis of TB and rifampicin resistance detection.

Molbio has a strong global footprint, having sold over 12,500 devices across more than 90 countries through March 31, 2026. It has expanded beyond molecular diagnostics into digital radiology (via subsidiary Prognosys, brand "ProRad") and digital pathology (via subsidiary OptraScan. The Company operates in an oligopolistic market with high entry barriers.

2. Business Model and Revenue Streams

Revenue Architecture — "Razor-and-Blade"

Molbio's revenue is driven by two interlinked product categories, with the consumable test kits forming the recurring-revenue engine:

• Devices (razor): The Truenat platform comprises the Trueprep universal nucleic acid extraction device (automated sample preparation) and the Truelab real-time PCR analyzer, available in three variants — UnoDx, Duo and Quattro — running one, two and four tests simultaneously.
• Test kits (blade): Disease-specific, ready-to-use, room-temperature-stable, single-use consumables pre-loaded with reagents. These lock in recurring revenue since they work exclusively with Truenat instruments.

Combined device and test-kit revenue was ₹1,238.10 Crore (FY2026), ₹933.92 Crore (FY2025) and ₹737.23 Crore (FY2024).

Customer & Channel Concentration

The Company's revenue is heavily concentrated in government and public-health channels, which represents both scale advantage and concentration risk:

Revenue split by customer type (finished goods) for FY2026: Indian State/Central government’s 23.29% + 56.52%, international aid agencies 4.75%, and non-government agencies 15.44%.

Geographic Mix

Pricing Advantage

Per the 1Lattice Report, the Truenat platform is cost-effective on a long-term basis in terms of both initial capital expenditure for installation and recurring cost per test, versus centralised PCR laboratory infrastructure.

3. Products and Service Portfolio

Core Molecular Diagnostics (Molbio / Company-operated)

• Truenat Platform (Devices): Trueprep extraction device + Truelab analyzer (UnoDx/Duo/Quattro variants). 30 diseases commercialised, 43 assays as of FY2026 (vs 26 diseases / 38 assays in FY2024).
• Truenat Test Kits (Consumables): 17.56 million test kits sold in FY2026 (vs 12.24 million in FY2025 and 8.80 million in FY2024). 2,524 devices sold in FY2026.

Adjacent Portfolio (via Subsidiaries)

• Prognosys ("ProRad" brand): Digital X-ray imaging — ultraportable, mobile digital, floor/ceiling-mounted X-ray and C-arm systems; also veterinary imaging products and software. Acquired March 2023 (65.47% stake).
• OptraScan: Digital pathology scanners, AI-powered analysis tools and telepathology services (60.00% investment agreement, October 2024).

Manufacturing Footprint & Capacity Utilisation

Six manufacturing facilities in India (Goa ×2, Bengaluru ×2, Visakhapatnam, Pune). Installed capacity: 5,400 devices p.a. and 39,000,000 Truenat test kits p.a. (as of March 31, 2026).

Low-to-moderate utilisation signals substantial headroom for volume growth without major incremental capex — a key operating-leverage lever.

Quality & Certifications

Quality management system certified by TÜV SÜD under ISO 13485 and MDSAP, compliant with CDSCO, EU, ANVISA (Brazil), Health Canada and US FDA criteria.

4. Key Business Strengths

• Large addressable market with structural tailwinds: Global POCT TAM of USD 29.3 billion (₹2,588.6 billion) in 2025, projected to grow at a 17.9% CAGR to USD 67.1 billion by 2030 (1Lattice Report), with the Company well placed to capture unmet molecular-diagnostics demand.
• WHO-endorsed, regulatory-moated flagship product: Truenat TB chip is the only Indian-developed and one of only two globally WHO-endorsed rapid molecular TB tests — a durable competitive barrier reinforced by 13 years of R&D and ICMR certification.
• Deep IP portfolio: 16 patents, 29 trademarks, 11 designs and 3 copyrights in India, plus 191 patents in foreign jurisdictions (US, China, Singapore), creating high entry barriers.
• Recurring-revenue razor-and-blade model: Proprietary lock-in between Truenat instruments and single-use test kits drives high-visibility, annuity-like consumable revenue.
• R&D-led innovation engine: Dedicated Bengaluru R&D unit (153 employees, incl. 136 scientists) with R&D spend of ₹87.46 Crore in FY2026 (6.05% of revenue).
• Strong operating scale-up and profitability: Revenue nearly doubled from ₹836.56 Cr (FY2024) to ₹1,445.69 Cr (FY2026); PAT rose from ₹83.54 Cr to ₹164.14 Cr; ROE of 15.59% and ROCE of 17.55% (FY2026).
• Marquee institutional backing: Supported by Motilal Oswal (India Business Excellence Fund III) and Temasek (via V Sciences Investments), lending capital and strategic depth.

5. Future Growth Strategy

• Geographic expansion: Deepen presence across India and globally, building on a base of 90+ export countries and 12,500+ installed devices.
• Menu expansion: Continue expanding the suite of diagnostic solutions across additional infectious and non-communicable diseases on the existing Truenat platform.
• New platform development: Leverage R&D to develop new POC platforms using advanced multiplex PCR for other communicable and non-communicable diseases.
• Inorganic growth & Centre of Excellence: Pursue strategic acquisitions and alliances and establish a dedicated Centre of Excellence — a primary use of IPO proceeds (₹105.54 Crore towards the R&D facility and CoE).
• Capacity monetisation: Convert existing low-utilisation installed capacity (devices 42.30%, kits 58.25%) into volume growth with minimal incremental capex, aided by EMS-vendor flexibility.
• Portfolio diversification: Scale adjacent radiology (ProRad) and digital pathology (OptraScan) franchises, including veterinary and AI-enabled telepathology offerings.